Healx Enters Agreement to Use Its AI Platform to Discover New Rare Indications for Discontinued Sanofi Compound

Rare Daily Staff

Healx, which uses its AI-driven platform Healnet for rare disease drug discovery, said it will work with Sanofi to identify new rare disease indications for one of its compounds.

Under the agreement, Sanofi will provide data related to a late-stage discontinued asset that is being considered for out-licensing. Financial terms of the partnership were not disclosed.

“Today, only 5 percent of rare diseases have an approved treatment. At Healx, our mission is to ensure that no potential therapy is overlooked,” said Tim Guilliams, co-founder and CEO of Healx. “This collaboration is a testament to the strength of our platform in potentially identifying new rare disease indications, and we are delighted to partner with Sanofi to unlock the power of our unique AI toolset in the service of patients in need.”

Though there is much excitement about the potential to use AI to identify new therapies, the technology can also be harnessed to find new uses for existing therapies. Additionally, it can help rescue potential therapies that, for one reason or another, are no longer being pursued for clinical development.

Healnet incorporates recent advances in generative AI to find connections between biological and chemical entities that could be turned into new treatments. Healx has built a suite of technologies to rapidly identify and progress new therapies for some of the 95 percent of rare diseases currently without an approved treatment.

Healx will use its drug discovery and development expertise to provide Sanofi with an AI-driven therapeutic rationale to support the compound’s future development.

Photo: Tim Guilliams, co-founder and CEO of Healx